ICU醫療 ICUI 深 滬
已收盤 02-06 16:00:00 美东时间
154.16
+4.520
+3.02%
華盛通- 最 高154.79
- 今 開151.01
- 成交量 22.33万股
- 最 低 149.05
- 昨 收 149.64
- 總市值 38.06亿
- 52周最高 165.17
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 107.00
- 委 比 -34.50%
- 總股本 2468.67万
- 歷史最高 321.70
- 量 比 0.88
- 振 幅 3.84%
- 歷史最低 35.58
- 每 手 1
- 風險率 11.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多US FDA Says ICU Medical Recalling IV Gravity Burette Set Due To Burette Component Missing Internal Shut-Off Valve Intended To Stop Fluid Flow
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/intravascular-administration-set-recall-icu-medical-removes-iv-gravity-burette-set
2025-12-30 23:24
InfuSystem Pain Management Infusion Pumps To Receive Separate Medicare Payment Under NOPAIN Act Starting January 1, 2026
Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026 Rochester Hills, Michigan, December 10, 2025 - InfuSystem Holdings,
2025-12-11 06:36
ICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
<p>ICU Medical, Inc. announced that its management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on December 4, 2025, at 10:00 a.m. PT (1:00 p.m. ET). The company will also conduct one-on-one meetings on the same day. The fireside chat will be webcast live and available for replay on the company’s website under the Investors tab. ICU Medical specializes in innovative medical products used i...
2025-11-20 13:30
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
电话会总结 ｜ ICU Medical(ICUI)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据ICU Medical 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收5.33亿美元，有机增长5% - 消耗品业务营收增长8%（报告增长）和7%（有机增长），创下季度销售记录 - IV系统业务营收增长9%（报告增长）和8%（有机增长） - 重症护理业务营收下降52% **盈利能力：** - 毛利率提升近0.5个百分点，主要受益于400万美元意大利回款责任一次性结算收益和整合协同效应 - 调整后EBITDA达到1.06亿美元 - 调整后稀释每股收益2.30美元 - 运营费用1.30亿美元
2025-11-07 12:09
美股盘后 | ICU医疗涨10.63%
ICU医疗将于11月6日盘后发布2025年第三季度财报，市场预期每股盈利1.31美元，营收5.1267亿美元，投资者将密切关注业绩表现是否符合预期。
2025-11-07 07:29
ICU Medical shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 adjusted EPS guidance above estimates.
ICU Medical shares are trading higher after the company reported better-than-ex...
2025-11-07 05:37
ICU Medical Q3 Adj. EPS $2.03 Beats $1.43 Estimate, Sales $536.990M Beat $510.440M Estimate
ICU Medical (NASDAQ:ICUI) reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.43 by 41.66 percent. This is a 27.67 percent increase over earnings of $1.59 per share from the
2025-11-07 05:14
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
